title: Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia.
abstract: Numerous drugs and compounds have been validated as protecting against myocardial ischemia (MI), a leading cause of heart failure; however, synergistic possibilities among them have not been systematically explored. Thus, there appears to be significant room for optimization in the field of drug combination therapy for MI. Here, we propose an easy approach for the identification and optimization of MI-related synergistic drug combinations via visualization of the crosstalk between networks of drug targets corresponding to different drugs (each drug has a unique network of targets). As an example, in the present study, 28 target crosstalk networks (TCNs) of random pairwise combinations of 8 MI-related drugs (curcumin, capsaicin, celecoxib, raloxifene, silibinin, sulforaphane, tacrolimus, and tamoxifen) were established to illustrate the proposed method. The TCNs revealed a high likelihood of synergy between curcumin and the other drugs, which was confirmed by in vitro experiments. Further drug combination optimization showed a synergistic protective effect of curcumin, celecoxib, and sililinin in combination against H₂O₂-induced ischemic injury of cardiomyocytes at a relatively low concentration of 500 nM. This result is in agreement with the earlier finding of a denser and modular functional crosstalk between their networks of targets in the regulation of cell apoptosis. Our study offers a simple approach to rapidly search for and optimize potent synergistic drug combinations, which can be used for identifying better MI therapeutic strategies. Some new light was also shed on the characteristic features of drug synergy, suggesting that it is possible to apply this method to other complex human diseases.
authors: Department of Geriatrics, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
authors: Xiaojing
authors: X
authors: Wan
authors: Department of Geriatrics, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
authors: Jia
authors: J
authors: Meng
authors: Department of Cardiology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
authors: Yingnan
authors: Y
authors: Dai
authors: Department of Geriatrics, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
authors: Yina
authors: Y
authors: Zhang
authors: Department of Endocrinology, the Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
authors: Shuang
authors: S
authors: Yan
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D000068579:Celecoxib; D002478:Cells, Cultured; D003474:Curcumin / Q000494:pharmacology*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000379:methods; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077385:Silybin; D012838:Silymarin / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D012838:Silymarin; D013449:Sulfonamides; D000077385:Silybin; D003474:Curcumin; D000068579:Celecoxib